Nautilus Biotechnology is trading at $2.12, down 7.42% during the November 5 session; no company-specific announcement explaining the decline was identified. - The investor-relations page lists third-quarter results from October 27 as the company’s latest release. - Broader market weakness may be contributing: the Nasdaq is down 2.03%. - Biotech context is mixed: XBI is up 2.05%, so sector performance does not explain the decline as a sector-wide move.